Consider participating in a clinical study investigating a potential treatment for Focal Segmental Glomerulosclerosis (FSGS) with and without Nephrotic Syndrome
FSGS: a rare kidney disease
Chemokine Receptor 2 (CCR2) normally causes immune cells to move into a part of the body that is inflamed. In addition, certain cells in your kidney may be negatively affected by CCR2 which leads to high protein levels in your urine.
The medication being studied, CCX140-B is designed to block CCR2. When CCX140-B is given, it blocks CCR2 and may reduce injury of these kidney cells
Participate in the study
CCX 140-B is an investigational medication being studied to learn if it is safe and effective for the treatment of FSGS with or without Nephrotic Syndrome.
The study medication has been tested before in patients with diabetes with kidney disease and abnormal protein excretion in the urine.
Find out if you are eligible
If tests have detected abnormally high protein in your urine, it may be one of the signs that led to your diagnosis of FSGS and Nephrotic syndrome.
If you meet the requirements, you may be eligible to participate in the LUMINA study.
Are You Eligible to Participate?
Take the survey, and get a referral to a study site near you.
If you answered “yes” to all of these questions you may be eligible
The information you provide will not be stored, but only used to determine if you are eligible for the study. Please note you are only eligible to take this survey or participate in the study if you are over 18 years old.